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During the last decade, the health sciences have experienced a major
shift in orientation. With the rise of genomics and advances in
molecular biology, scientists have increasingly moved away from
population-based approaches to health toward studies of disease sus-
ceptibility among individuals. That change is reflected by the push
for personalized medicine, which targets the underlying susceptibili-
ties that make some people prone to particular diseases. It’s also
reflected by recent goals for personalized exposure assessment in
environmental health, and efforts to understand why some people
seem particularly vulnerable to the harmful effects of pollution and
other environmental toxicants. 
The focus on individuals could make public health strategies more
effective by allowing practitioners to direct resources toward those
with the greatest need. But the success of these efforts will depend
largely on the continued identification of biomarkers that reflect the
individual’s health status and risk at key time points. 
Scientists rely on biomarkers to track each phase of the
dose–response continuum, from exposure through effect. In a broad
sense, biomarkers include physical parameters that can be clearly 
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anchored to a disease or class of diseases. In
medicine, they can include measures such
as heart rate or serum cholesterol, both of
which correlate directly with cardiac disease
risk. For environmental health purposes,
biomarkers include a range of additional
exposure-related indices, such as pollutant
measures in tissues and bodily fluids; expo-
sure-induced changes in cells, proteins,
DNA, and other molecules; and inherited
gene variations that influence how individ-
uals respond to their environments. Single-
nucleotide polymorphisms (SNPs), for
instance, which are simple inherited gene
variations, can increase or lessen disease
susceptibility following environmental
exposures.
Biomarker investigations are now an
integral part of environmental health
research. Through its Exposure Biology
Program, established in 2006, the NIEHS
will commit substantial resources to the
search for biomarkers, focusing particularly
on those that reflect the human response to
environmental agents. Likewise, the EPA
Office of Research and Development has
committed at least $3 million annually since
2000 to biomarker investigations.
But even as the public health communi-
ty ramps up its efforts in this area, the
search for new biomarkers has been slow
and often frustrating. Scientists can pro-
pose biomarkers on the basis of animal
research or limited studies in humans, but
to confirm their relevance to broad human
populations, biomarkers must be validated
in population-based studies often involving
large cohorts, ideally using prospective
studies that involve repeated sampling of
individuals. 
Repeated sampling assures scientists
that biomarkers reflect actual disease
processes, instead of measurement errors or
other incidental variations. Yet prospective
studies that incorporate multiple sampling
rounds for biomarker validation are time-
consuming and expensive, so very few have
been conducted, says John Groopman,
chairman of the Department of Environ-
mental Health Sciences at the Johns
Hopkins Bloomberg School of Public
Health. “That really hinders our ability to
make intermediate linkages between expo-
sure and disease outcome,” he explains.
Consequently, biomarkers that reflect the
full response spectrum from exposure
through effect have been identified for just
a few agents, notable among them benzene,
aflatoxin B1, and UV radiation. 
The Basis of the Field
The use of biomarkers in the environmental
health sciences arguably dates back to the
early 1970s, with Herbert Needleman’s
groundbreaking work on lead neurotoxicity
in children. Now a professor at the University
of Pittsburgh Medical Center, Needleman
was an assistant professor at Harvard Medical
School when he used blood lead as a bio-
marker to show that even at the lowest
detectable levels, lead could impair a child’s
IQ. With that finding, he conclusively linked
a lead biomarker to cognitive decline and
sparked efforts to remove the metal from
gasoline, which was the largest source of
human exposure at the time. 
But though Needleman was using blood
lead as a biomarker, he didn’t articulate it as
such. The terminology used in biomarker
research today didn’t actually emerge until
the early 1980s. During that time, environ-
mental health sciences professor Frederica
Perera and medical professor I. Bernard
Weinstein, both of the Columbia Universi-
ty Mailman School of Public Health, pro-
posed molecular epidemiology—the use of
biomarkers to link human environmental
exposures with illness—as a new approach
to the study of cancer. They also proposed
four categories of biomarkers: internal dose,
biologically effective dose, early biologic
response, and susceptibility. They suggested
that exposure assessment should turn its
focus from population-based estimates of
dose to the quantification among individu-
als of biologically effective dose, defined as
the amount of a chemical interacting with
critical cellular targets. 
In a paper published in volume 3, issue
12 (1982) of Carcinogenesis with colleagues
from the National Cancer Institute (NCI),
Perera and Weinstein reported that they had
detected cellular adducts of DNA and the
carcinogen benzo[a]pyrene in lung tissue,
and in several cases blood cells. In that par-
ticular case, the adduct was the biomarker,
and the critical cellular target was DNA. But
the numbers of patients tested in the study
was too small to draw definitive conclusions
about risk. 
Even so, the concept of a biologically
effective dose survived and flourished in the
scientific literature. Scientists acknowledged
that to fully understand toxic responses, they
would have to identify key events along the
pathway from exposure to disease. But their
early efforts to do so were limited in part by
the lack of an organized framework for pur-
suing biomarker studies, says Nathaniel
Rothman, a senior investigator in the NCI’s
Occupational and Environmental Epidemi-
ology Branch. 
“[Scientists] would try to communicate
with each other, but sometimes it would be
like ships passing in the night,” he says.
“One would be talking about using an
exposure biomarker to ask one type of
research question, and another about apply-
ing an early biologic effect marker to ask a
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different research question, and neither
would realize they weren’t talking about
quite the same thing.” 
In 1987, the National Research Council
convened a committee to investigate how
biomarkers were being developed and used
in the environmental health sciences. The
conclusions were documented in a seminal
paper published in the October 1987 issue
of EHP, which described the four basic bio-
marker groupings still in use today: exposure
biomarkers (which include markers of
external exposure and of internal dose); bio-
markers of biologically effective dose; effect
biomarkers (which include markers of health
impairment or recognized disease, early dis-
ease precursors, or peripheral events that pre-
dict health impairment); and susceptibility
biomarkers (which include intrinsic genetic
or other characteristics or preexisting dis-
eases that result in an increase in internal
dose, biologically effective dose, or target tis-
sue response).
The 1987 paper also introduced the con-
cept of a “continuum of biological events” in
toxicity, and proposed that biomarkers could
be used to delineate each event within the
continuum, from exposure, to internalized
dose, to biologically effective dose, to altered
molecular structure, and finally to clinical
disease. 
“These articles really made a critical con-
tribution,” Rothman says. “They helped
codify terms and gave everyone a flexible
structure to work with.” 
Adductive Reasoning
During the next decade, biomarker research
took hold and produced some important
success stories, particularly in the area of
exposure biomarkers. The emphasis on
exposure was driven by growing excitement
over the adducts that some chemicals form
with proteins and DNA. As biomarkers,
adducts serve a number of key purposes:
they reflect individual exposures, and they
also focus exposures on key toxicological tar-
gets within the cell. What’s more, adducts
can provide evidence for metabolic steps in
the exposure–response continuum. That’s
because some compounds can bind with
proteins or DNA only after being metaboli-
cally transformed. 
Groopman was one of the first to con-
clusively link DNA adducts with disease,
specifically human liver cancer induced by
aflatoxin B1, a carcinogenic product of a
mold found on peanuts and other grains.
Using experimental animals, he started by
showing that aflatoxin exposure was reflect-
ed in DNA–aflatoxin adducts in urine. He
then demonstrated that the biomarkers
could be detected in human urine samples
obtained from exposed populations in Asia.
Equally significant, he found the adduct
concentrations rose in proportion to dose,
thus confirming their value as quantifiable
indicators of personal exposure. Finally, in a
classic nested case–control study carried out
in a cohort in Shanghai and described in the
September 1994 issue of Cancer Epidemi-
ology Biomarkers & Prevention, he showed
that a urinary DNA–aflatoxin adduct was
more strongly associated with risk of liver
cancer than urinary aflatoxin metabolites. 
“This was significant, because Groop-
man showed that DNA adducts reflected
more than just aflatoxin exposure,” says
Rothman. “He also showed that people with
liver cancer, given detectable levels of any
measured aflatoxin metabolite, had a ten-
dency to produce more DNA adducts,
which suggests that this biomarker incorpo-
rates other meaningful information.”
Further, Groopman and his colleagues
showed that biomarkers of aflatoxin expo-
sure interacted with hepatitis B infection to
produce very high risks of liver cancer.
One of the consequences of unrepaired
DNA–aflatoxin adducts is mutation in can-
cer-related genes. In the early 1990s, NCI
Laboratory of Human Carcinogenesis chief
Curtis Harris, Mehmet Ozturk of Harvard
Medical School, and their colleagues discov-
ered a specific aflatoxin-related mutation in
the p53 tumor suppressor gene in Chinese
and African populations occurring in liver
cancer from people exposed to aflatoxin and
infected with hepatitis B. This p53 muta-
tion can be measured in DNA from blood
plasma and has recently been shown to be a
biomarker of aflatoxin exposure and effect
by Ruggero Montesano and colleagues at
the International Agency for Research on
Cancer. 
Meanwhile, other researchers were also
making key advances. Lars Ehrenberg, a pro-
fessor at Stockholm University in Sweden,
showed that hemoglobin adducts could accu-
mulate a record of environmental exposure
extending over the life of red blood cells
(which averages roughly 120 days). Those
studies gave rise to the seminal work of
Steven Tannenbaum, a professor of toxicol-
ogy and chemistry at the Massachusetts
Institute of Technology, who demonstrated
that hemoglobin adducts with aromatic
amines could not only provide key expo-
sure biomarkers for these compounds, but
could also predict elevated risks for human
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bladder cancer. Stephen Hecht, a professor
of cancer prevention at the University of
Minnesota, found that DNA adducts with
tobacco-specific nitrosamines were out-
standing indicators of environmental
tobacco smoke exposure. According to
Groopman, Hecht’s work contributed key
advances to our understanding of tobacco
smoke exposures among both smokers and
nonsmokers, and catalyzed the movement
to reduce secondhand smoke exposure in
the United States. In a related
example, published in the Sep-
tember 2001 issue of Cancer Research, Perera
and colleagues at Harvard University
reported that polycyclic aromatic hydrocar-
bon (PAH)–DNA adducts in white blood
cells obtained from smokers enrolled in a
prospective cohort study predicted a three-
fold elevation in risk for subsequent lung
cancer.
Among the most comprehensive efforts
was work over the past 15 years by Rothman
and Martyn Smith, a professor of toxicology
at the University of California, Berkeley,
along with colleagues from the NCI, the
University of North Carolina at Chapel Hill,
and the Chinese Academy of Preventive
Medicine (now the Chinese Center for
Disease Control and Prevention). They
described the relationship between external
benzene exposure and urinary metabolites
with early biological end points, including
peripheral blood cell counts, chromosomal
aberrations, and more recently, biomarkers
identified by proteomic and expression array
technologies. This team also identified sub-
groups of workers who were particularly sus-
ceptible to some of these effects because of
genetic variations in metabolic and other
pathways. And showing how biomarker
studies have regulatory implications, they
provided evidence of alterations in hemato-
logic end points at benzene exposures of less
than 1 ppm, the current OSHA standard.
These findings appeared in the 3 December
2004 issue of Science. 
Taking a New Tack
Some of these studies are still ongoing today,
along with many more not described here.
But by the mid-1990s, it was clear that
although progress was somewhat steady for
exposure biomarkers—particularly for
adducts and urinary metabolites—compara-
ble advances were not being made for effects
biomarkers or markers of susceptibility. In
1995, members of the Mickey Leland Urban
Air Toxics Research Center, a research facili-
ty based in Houston, Texas, convened a sym-
posium to evaluate biomarker progress for a
range of air pollutants, including aromatics,
PAHs, and metals. At the symposium, par-
ticipants referred to a number of promising
exposure biomarkers, mainly adducts and a
variety of urinary metabolites. But among
the compounds evaluated, a putative effect
biomarker was available only for 1,3-
butadiene, that marker being an altered
white blood cell called the HPRT mutant
lymphocyte. Even this biomarker, the partic-
ipants noted, had uncertain value in envi-
ronmental settings with multiple low-level
exposures. As for susceptibility markers,
none were noted at all. 
Symposium participants felt that sever-
al factors constrained efforts to find bio-
markers of effects and susceptibility, among
them a lack of sufficient human toxicology
data, a shortage of epidemiological studies
to interpret measurements, uncertain expo-
sure assessments, and high analytical costs.
Another problem, experts noted at the time,
is that scientists sometimes didn’t give suffi-
cient thought to how the biomarkers they
were using fit with their study designs. And
that uncertainty led to problems with bio-
marker selection and interpretation of results. 
For instance, while some urinary metabo-
lites may be adequate to monitor recent,
short-term exposures, they may not be
appropriate to measure longer-term expo-
sures accumulated over weeks, months, or
years. Those metabolites, therefore, would be
best applied in cross-sectional study designs,
in which the main goal is to determine if a
particular compound has been absorbed and
excreted. These markers’ ability to indicate
long-term exposure, particularly for expo-
sures with substantial intraindividual varia-
tion, is limited, making them less suitable for
use in studies of patients with diseases that
have long latencies. 
An important step toward identifying
key methodologic issues pertaining to bio-
marker use was made in the text Molecular
Epidemiology: Principles and Practices by
Perera and Paul A. Schulte of the National
Institute for Occupational Safety and Health
(NIOSH). Following up on this work,
Rothman and colleagues at The Johns
Hopkins University and NIOSH produced
a framework to help scientists select the opti-
mal biomarkers for particular study designs,
or if need be, the best type of study design
for a given class of biomarkers. Published in
the June 1995 issue of Cancer Epidemiology
Biomarkers & Prevention, the framework
appeared in the form of a matrix that scien-
tists could use to match their selections
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appropriately. That matrix has since become
a standard biomarker teaching tool in sever-
al settings. 
“Our goal was to facilitate more effective
discussions and thinking about the use of
biomarkers in epidemiological studies,”
Rothman says. “I think it helped people
appreciate what kind of biomarker will work
and when. You really have to consider the
advantages and disadvantages of the markers
and studies you plan to use.” 
“Omics” and Beyond
As scientists pushed forward on biomarker
research during the 1990s, a profound
achievement was about to radically alter the
biomedical landscape. In June 2000, a pub-
lic–private partnership of the NIH and
Celera Genomics announced they had
completed a rough draft of the human
genome. With that announcement, bio-
marker studies entered a whole new era.
Enabled by robotic, high-throughput ana-
lytical instruments, which allowed them to
scan thousands of genes simultaneously, sci-
entists dramatically accelerated their efforts
to find new biomarkers. 
Today, scientists routinely compare
genomic stretches among patients and
healthy individuals, searching for gene varia-
tions that could provide markers of effect or
susceptibility. Those genes, meanwhile, pro-
duce proteins that also can serve as biomark-
ers, and in some cases, as targets for new
drugs and other health-protective interven-
tions. Thus, high-throughput “omic” sci-
ences including genomics, proteomics, and
metabolomics now drive major efforts in
biomarker selection and identification. “And
these new biomarkers have the potential to
give us a good deal of mechanistic informa-
tion,” says Harris. 
Even so, the dramatic increase in poten-
tial biomarkers hasn’t been matched by a rise
in useful, validated biomarkers. Scientists
still confront important challenges in their
efforts to use these indicators in epidemi-
ological investigations. According to
Rothman, new biomarkers have to meet the
same criteria as those selected in the past:
Are they accurate? Do they measure what
they purport to measure? Are they stable
and reliable in the laboratory? Are they suf-
ficiently sensitive? Are they sufficiently spe-
cific to the disease of interest? 
The tremendous enthusiasm for SNPs as
susceptibility biomarkers has been tempered
over time by a lack of successful identifica-
tions. John P.A. Ioannidis, a professor at the
University of Ioannina School of Medicine
in Greece, reports in a 4 October 2006 edi-
torial in the Journal of the National Cancer
Institute that among 16 SNPs implicated in
breast cancer, none were conclusively linked
to the disease by scientists participating in a
large-scale evaluation. Likewise, Ioannidis
adds that meta-analysis of 16 additional can-
didate gene variants for breast cancer
revealed what appeared to be questionable
significance with regards to the disease. 
Regina Santella, a professor of environ-
mental health sciences at the Mailman
School of Public Health, says, “The effects of
. . . SNPs are likely to be small. I think it’s
going to be really hard to find SNPs and
genotypes that we really believe have an
impact on health. It’s not going to be one or
two of them—it’s going to be multiple geno-
types interacting together.” 
Echoing that view, Harris suggests a
leading edge in research could be directed
toward multiple biomarkers—including
microRNA, mRNA, protein, and gene
expression profiles—linked by integrated
models that predict disease risk according
to numerous factors. Adding to this,
Groopman says that scientists should also
consider biomarkers that describe how
environmental chemicals interact with
infectious agents and bacteria. 
“That’s a tremendously exciting opportu-
nity,” Groopman says. “Another area that’s
ripe for exploration concerns the examina-
tion of protein changes in blood as a conse-
quence of exposure and disease. The ability to
explore a well-established protein biomarker
repository in blood that we already have now
poses a major opportunity.” 
Yet even as these opportunities inspire
additional research, they also serve as a
reminder of how far we still have to go.
Biomarkers can reveal key aspects of the
body’s response to its environment and per-
haps suggest new strategies to protect public
health. But to realize those opportunities,
society itself must be willing to bear the costs
of biomarker validation and the ethical chal-
lenges that come with exposing individuals’
vulnerabilities to disease. Assuming those
conditions are met, the ambitious goals of
personalized medicine, with its commensu-
rate benefits, may one day be reached.
Charles W. Schmidt
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